Three Cities boosts COHR bid

Article

Independent service organization COHR of Chatsworth, CA, received good news this month when potential buyer Three Cities Funds of New York City increased its offer price for shares of COHR's common stock. Three Cities boosted its bid from $5.38 per share

Independent service organization COHR of Chatsworth, CA, received good news this month when potential buyer Three Cities Funds of New York City increased its offer price for shares of COHR's common stock. Three Cities boosted its bid from $5.38 per share to $6.50 per share.

COHR entered into a merger agreement with Three Cities in December, under which Three Cities bought a 48% interest in COHR at a price of $5.13 per share. A few days later, Three Cities made a bid for COHR's remaining stock at the $5.38 price (SCAN 1/13/99). The deal allowed for a price increase of $1 per share if COHR could settle pending shareholder lawsuits before the Feb. 3 expiration date under terms that would not require COHR to pay more than $3 million net of insurance proceeds.

But Three Cities increased its offer when COHR received a bid from a third party that proposed payment of $7 per share if the third party could complete due diligence and merger negotiations satisfactorily. Although the third party's bid proposed more per share, Three Cities' modified offer gives COHR the advantage of more immediate payment and none of the third party's due diligence requirements. Three Cities' revised bid expires Feb. 24 and is not contingent on COHR's settlement of shareholder suits.

Recent Videos
Incorporating CT Colonography into Radiology Practice
What New Research Reveals About Computed Tomography and Radiation-Induced Cancer Risk
What New Interventional Radiology Research Reveals About Treatment for Breast Cancer Liver Metastases
New Mammography Studies Assess Image-Based AI Risk Models and Breast Arterial Calcification Detection
Can Deep Learning Provide a CT-Less Alternative for Attenuation Compensation with SPECT MPI?
Employing AI in Detecting Subdural Hematomas on Head CTs: An Interview with Jeremy Heit, MD, PhD
Pertinent Insights into the Imaging of Patients with Marfan Syndrome
What New Brain MRI Research Reveals About Cannabis Use and Working Memory Tasks
Current and Emerging Legislative Priorities for Radiology in 2025
How Will the New FDA Guidance Affect AI Software in Radiology?: An Interview with Nina Kottler, MD, Part 2
Related Content
© 2025 MJH Life Sciences

All rights reserved.